磷酸西他列汀
鼻腔给药
壳聚糖
磷酸西他列汀
医学
纳米颗粒
药理学
Zeta电位
化学
吸收(声学)
材料科学
核化学
内科学
纳米技术
内分泌学
生物化学
糖尿病
2型糖尿病
复合材料
作者
Barnabas Wilson,Bashir Nasralla Mohamed Alobaid,K Geetha,Josephine Leno Jenita
标识
DOI:10.1016/j.jddst.2020.102176
摘要
Alzheimer's disease (AD), a highly complex, irreversible, progressive, challenging as well as fatal neurodegenerative disease of the brain, affects 35 million people around the world. It is estimated that 100 million people are expected to suffer from the disorder by 2050. It was found that sitagliptin (SIT), a dipeptidyl peptidase-4 (DPP-4) inhibitor, produced symptomatic relief of AD. Sitagliptin loaded chitosan nanoparticles (SIT-CS-NPs) were prepared and evaluated for their potential to target sitagliptin into the brain following intranasal (IN) administration. The SIT-CS-NPs were formulated by ionic gelation method. The mean size and zeta potential was 188.4 ± 48.1 nm and 20.8 mV respectively. In vitro SIT release in pH 6.4 phosphate buffer ranged between 49.55 ± 2.62 %w/w and 73.77 ± 2.12 %w/w for 24 h. Animal studies revealed that SIT-CS-NPs increased SIT levels in the brain by 5.07 fold in comparison with free SIT after IN administration.
科研通智能强力驱动
Strongly Powered by AbleSci AI